Janssen Biotech
| Centocor | |
|---|---|
| legal form | subsidiary |
| founding | 1979 |
| Seat |
Horsham , Pennsylvania ,
|
| Branch | Biotechnology, pharmacy |
| Website | www.janssenbiotech.com |
Janssen Biotech Inc is a US biotechnology company founded in 1979 as Centocor Ortho Biotech Inc. in Philadelphia . Centocor has been part of Johnson & Johnson since 1999 and was renamed in 2011. Janssen Biotech is headquartered in Horsham , Pennsylvania .
Centocor was originally founded to develop monoclonal antibodies for diagnostic purposes. Centocor developed a test to diagnose the Rabies virus in 1982 . In 1998, Centocor brought Remicade ( infliximab ), a commonly used monoclonal antibody for Crohn's disease, to market . Remicade is also used today for the treatment of rheumatoid arthritis , psoriasis and in other indications.
The liposome Doxil ( doxorubicin ) and the platelet aggregation inhibitor ReoPro ( abciximab ) followed in 2005 .
In 2007, Stelara, the human monoclonal antibody ( ustekinumab ) for the treatment of psoriasis and Simponi ( golimumab ) for the treatment of rheumatic inflammatory diseases and chronic inflammatory bowel diseases, were approved.
2011 Zytiga (came abiraterone ) for hormone therapy to market. In the same year Centocor Ortho Biotech Inc. changed its name to Janssen Biotech Inc.
Individual evidence
- ↑ Our History Janssen Biotech WebSite, accessed September 11, 2013.
- ↑ Contact Us Janssen Biotech WebSite, accessed September 11, 2013.